linjc16/ctgov huggingface dataset:
Lung Cancer ID (Identity) Study

Study Overview
=================
Brief Summary
-----------------
The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.

Official Title
-----------------
Demographic, Clinical, Histological and Molecular Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohort: an Observational Cohort Study: Lung Cancer ID Study

Conditions
-----------------
Lung Cancer Stage IV

Intervention / Treatment
-----------------
* Other: Advanced lung cancer patients' group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years Suspicion of lung cancer based on imaging (CT and/or PET/CT) Indication to a biopsy for diagnosis, staging and/or molecular profiling Exclusion Criteria: Inability or unwillingness to provide a written informed consent ECOG performance status (>3) which makes a tissue diagnosis unfeasible ASA 4 status TNM Stage I-III

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of histologic subtypes | The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of histologic subtypes according to clinical and radiological characteristics | The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics | 24 months | 
| Molecular profiling | Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology | 24 months | 
| Time to diagnosis | Time lag between onset of symptoms (if any) and invasive testing | 24 months |
Ultrasonographic Prognostic Scale of Periventricular Hemorrhagic Infarction

Study Overview
=================
Brief Summary
-----------------
Observational study of preterm infant with a gestational age < 30 weeks born between 2017-2023 in Neonatal Care Unit in Gregorio Marañon Hospital (Madrid, Spain). We use a new ultrasonographic prognostic scale of periventricular hemorrhagic infarction for neurodevelopmental outcome at age 2 years.

Official Title
-----------------
Ultrasonographic Prognostic Scale of Periventricular Hemorrhagic Infarction in Preterm Infants With Gestational Age <30 Weeks

Conditions
-----------------
Preterms, Infarction Cerebral

Intervention / Treatment
-----------------
* Diagnostic Test: Routine cranial ultrasounds


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestacional Age < 30 weeks Exclusion Criteria: Brain malformation Genetic syndrome Metabolic disorders Chromosomal abnormality None cranial ultrasound
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Routine cranial ultrasounds|we will use the routine cranial ultrasounds|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Periventricular Hemorrhagic Infarction | Yes or no | first month | 
| Characteristic Sonographic |  | first month | 
| Neurodevelopmental outcome at age 2 years |  | first month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medical records |  | first month |
Blood Pressure Monitor Clinical Test (Cuff Range: 13.5cm-22cm)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify the accurancy of the blood pressure monitor device. Cuff size of arm circumference: 13.5cm- 22cm.

Official Title
-----------------
Blood Pressure Monitor#Model#BP7# Clincial Test

Conditions
-----------------
Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal blood pressure and hypertensive patients over 12 years old Exclusion Criteria: Patients with serious arrhythmias or a high frequency of arrhythmias pregnant woman Other investigators believe that it is not suitable to participate in this clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subject use both BP7 Wrist Automatic Electronic BPM and mercury sphygmomanometers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure monitor accurancy | All the test results of the electronic blood pressure monitor is within the accuracy creteria, with the merury sphygmomanometer as control | 30 minutes |
Understanding Engagement Trends in Chondrosarcoma Clinical Trials

Study Overview
=================
Brief Summary
-----------------
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.

Official Title
-----------------
Understanding Engagement Trends in Chondrosarcoma Clinical Trials: Investigating Participation Patterns Among Chondrosarcoma Patients

Conditions
-----------------
Chondrosarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Able to comprehend the investigational nature of the protocol and provide informed consent Diagnosis of chondrosarcoma Exclusion Criteria: No diagnosis of chondrosarcoma confirmed Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of chondrosarcoma patients who decide to enroll in a clinical trial |  | 3 months | 
| Rate of chondrosarcoma patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chondrosarcoma
Cognitive, Psychological, and Physical Functioning in Long-COVID Patients With Different Levels of Fatigue.

Study Overview
=================
Brief Summary
-----------------
Post COVID-19 usually occurs 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Patients report a range of disabling symptoms such as fatigue, shortness of breath, cognitive impairment, memory loss and mental health and employment issues. This clinical heterogeneity complicates the identification of the appropriate needs and care. The aim of this cross-sectional study is to identify subgroups (clusters) of post COVID patients based on clinical symptoms, demographic characteristics, levels of fatigue and physical, cognitive and psychological functioning of the individuals.

Official Title
-----------------
Cognitive, Psychological, and Physical Functioning in Long-COVID Patients With Different Levels of Fatigue.

Conditions
-----------------
Post-Acute COVID-19 Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The participant must report current persisting symptoms (such as brain fog, anxiety, shortness of breath, headaches but also others) and indicate on the Post COVID-19 Functional Status Scale that these have an impact on everyday functioning (grade 2, 3, and 4). These symptoms need to be present for more than two months. Further inclusion criteria are: Fatigue Severity Scale (FSS) score > 4 Aged over 18 years old Willing to sign the digital informed consent Dutch speaking and Dutch understanding Be tested positive for COVID-19, i.e. by reverse transcription polymerase chain reaction (RT-PCR), computed tomography (CT) of the lungs, or symptom-based diagnosis by the general practitioner. Exclusion Criteria: Pregnant women Pacemaker, defibrillator Brain or nerve disorders Epilepsy A copper spiral or recent bone fracture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical evaluation | Hand grip strength (Jamar hand dynamometer) & Six Minute Walk Test (6MWT) | Day 1 | 
| Fatigue severity | Fatigue severity scale (FSS) | Day 1 | 
| Psychological evaluation | Anxiety and depression Scale (HADS); MINI-S, MINI International Neuropsychiatric Interview - Simplified (Overbeek & Schruers 2019) | Day 1 | 
| Cognitive evaluation | Multi-modal Evaluation of Sensory Sensitivity (MESSY); Montreal Cognitive Assessment (MoCA) | Day 1 |
A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease.

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational study is to measure how many people are overweight or obese amongst patients with a diagnosed cardiovascular disease (CVD). The study also aims to characterise the population including the presence of cardiovascular (CV) risk factors in a number of countries across the globe representing different geographies, ethnicities, as well as different healthcare systems.

Official Title
-----------------
Multi-centre Cross-sectional Observational Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease

Conditions
-----------------
Obesity, Overweight

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). Adults, age above or equal to 18 years at the time of signing informed consent. Have established CVD and equal to or greater than 1 follow up appointment following an acute event from at least one of the following: Prior myocardial infarction Prior stroke (ischemic or haemorrhagic stroke) Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) below 85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease Exclusion Criteria: Previous participation in this study. Participation is defined as having given informed consent in this study Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Patients with known congenital heart disease/malformation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| People with established CVD<br>Adults diagnosed with established CVD, attending routine medical care or follow-up in a cardiology clinic. | Other: No treatment given<br>* No treatment given<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overweight and obesity among patients with established CVD pooled across all countries | % of patients | At the time of patient enrolment (Day 1/Visit 1) |
The Connection Between Personality, Burnout, and Hypertension in Nigerian Bank Employees

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal study which we plan to examine the link between personality traits, burnout, and hypertension in bank employees in South-eastern Nigeria

Detailed Description
-----------------
This proposed longitudinal study aims to examine the relationship between personality traits, burnout, and hypertension in bank employees in South-eastern Nigeria, where hypertension is a significant public health issue. The study will involve bankers as participants, who will be asked to complete self-report questionnaires and measure their blood pressure over four weeks. The research seeks to determine if personality differences and burnout levels contribute to hypertension risk in this population. By understanding the role of psychosocial factors in hypertension risk, the study hopes to provide recommendations for workplace adjustments that could improve employee well-being and reduce hypertension risk among Nigerian bank employees.

Official Title
-----------------
High Stakes, High Pressure: The Connection Between Personality, Burnout, and Hypertension in Nigerian Bank Employees

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Blood Pressure measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any staff of the Bank Exclusion Criteria: Non Staff
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood Pressure measurement|Blood Pressure measurement|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Pressure | Blood Pressure measurement | 20 minutes |
Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Our aim is to assess the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole versus Q-switched Nd:YAG laser in the treatment of OM.

Official Title
-----------------
Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial

Conditions
-----------------
Onychomycosis of Fingernail

Intervention / Treatment
-----------------
* Drug: Topical tioconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Age group >18 years. Patients of both genders. Patients with OM any type. Exclusion Criteria: • Pregnancy Localized bacterial infection around the affected nail Concomitant nails disease that causes nail dystrophy or discoloration such as psoriasis, lichen planus and atopic dermatitis that may interfere with diagnosis and treatment Hypersensitivity to terbinafine Intake of oral antifungal medication within the last 3 months or used topical antifungal medication within the last 2 weeks prior to the laser treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fractional CO2 laser combined with topical tioconazole<br>Fractional CO2 laser (10,600 nm) will be done. The sessions will be done every 2 weeks. Topical tioconazole 28% nail solution will be applied in between the sessions twice daily | Drug: Topical tioconazole<br>* Laser<br>* Other names: Laser;|
| Active Comparator: Q switched ND-Yag<br>Laser protocol with a specific parameters will be applied on the affected nails. In one session two passes across each nail plate will be performed with two minutes pauses between each pass. Sessions will be done every 2 weeks | Drug: Topical tioconazole<br>* Laser<br>* Other names: Laser;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment of onychomycosis | Patient Evaluation (Clinical percentage of improvement). 2- Improvement of OM (assessed by investigator). 3-Percentage of grading and OSI score improvement | 6 months |
Outcome Analysis of Endoscopic Resection of Pituitary Adenomas

Study Overview
=================
Brief Summary
-----------------
The goal of this prospective study is to learn about the operative outcomes in patients with pituitary adenoma who receive endoscopic resection. The main question it aims to answer is: • What are the outcomes of patient following endoscopic resection? including visual, hormonal, survival, and functional outcomes. Participants' data including clinical history, laboratory data, radiographic images, intraoperative videos will be evaluated and analyzed.

Official Title
-----------------
Analysis of Operative Outcomes Following Endoscopic Resection of Pituitary Adenomas

Conditions
-----------------
Pituitary Adenoma

Intervention / Treatment
-----------------
* Procedure: Endoscopic endonasal surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient Pathological diagnosis of pituitary adenoma Underwent endoscopic endonasal resection Exclusion Criteria: Age < 18 or > 80 years Non-pituitary adenoma pathologies Underwent non-endoscopic surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Endoscopic endonasal surgery<br>Patients who received endoscopic endonasal resection of pituitary adenomas | Procedure: Endoscopic endonasal surgery<br>* Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual field | The postoperative visual field will be assessed with standard visual perimetry and compared with preoperative measurements. | 6 months | 
| Diabetes insipidus | Postoperatively, the patient's urine output and urine specific gravity will be measured to determine if the patient had diabetes insipidus. If the patient had diabetes insipidus, the duration of the diabetes insipidus will be recorded. | 6 months | 
| Cortisol level | Postoperative serum cortisol level will be measured and compared to preoperative levels. | 6 months | 
| Thyroid hormone level | Postoperative serum TSH and free T4 level will be measured and compared to preoperative levels. | 6 months | 
| Prolactin level | Postoperative serum prolactin level will be measured and compared to preoperative levels. | 6 months | 
| IGF-1 level | Postoperative serum IGF-1 level will be measured and compared to preoperative levels. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pituitary adenoma